“Bak (and Bax) to the Future” — of Primary Melanoma Prognosis?
Authors:
- 1 June 2006
- journal article
- editorial
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 126 (6) , 1212-1214
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Loss of Proapoptotic Bcl-2-Related Multidomain Proteins in Primary Melanomas Is Associated with Poor PrognosisJournal of Investigative Dermatology, 2006
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathJournal of Experimental Medicine, 2005
- Distinct Sets of Genetic Alterations in MelanomaNew England Journal of Medicine, 2005
- Caspases: pharmacological manipulation of cell deathJournal of Clinical Investigation, 2005
- Melanoma genetics and the development of rational therapeuticsJournal of Clinical Investigation, 2005
- Immunogenicity of Bcl-2 in patients with cancerBlood, 2005
- Targeting death receptors in cancer with Apo2L/TRAILCurrent Opinion in Pharmacology, 2004
- Imiquimod: Unexpected KillerJournal of Investigative Dermatology, 2004
- The Bcl-2 family: roles in cell survival and oncogenesisOncogene, 2003
- Selective Expression of FLIP in Malignant Melanocytic Skin LesionsJournal of Investigative Dermatology, 2001